Compare ResMed Inc. (RMD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs BIO-TECHNE Corp — how do they compare? ResMed Inc. trades at $196 (market cap $28.81B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: ResMed Inc. is far larger — about 2.6× BIO-TECHNE Corp's market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| RMD | TECH | |
|---|---|---|
Market Cap | $28.81B | $11.16B |
Sector | Health | Health |
52-Week High | $293.73 | $72.12 |
52-Week Low | $182.82 | $43.31 |
Enterprise Value | $27.99B | $11.24B |
Dividend Yield | 1.21% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
